Greenwich LifeSciences (GLSI) Competitors $8.84 -0.11 (-1.23%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. DNTH, ORGO, GHRS, ALMS, QURE, BCYC, KURA, URGN, MGTX, and IMTXShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Dianthus Therapeutics (DNTH), Organogenesis (ORGO), GH Research (GHRS), Alumis (ALMS), uniQure (QURE), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Dianthus Therapeutics Organogenesis GH Research Alumis uniQure Bicycle Therapeutics Kura Oncology UroGen Pharma MeiraGTx Immatics Dianthus Therapeutics (NASDAQ:DNTH) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is DNTH or GLSI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,250.32% -21.68% -20.88% Greenwich LifeSciences N/A -185.12%-164.27% Which has more volatility and risk, DNTH or GLSI? Dianthus Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Which has better earnings and valuation, DNTH or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than Dianthus Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M98.98-$43.56M-$2.60-7.39Greenwich LifeSciencesN/AN/A-$8.89M-$0.80-11.19 Do analysts recommend DNTH or GLSI? Dianthus Therapeutics currently has a consensus target price of $54.33, indicating a potential upside of 182.84%. Greenwich LifeSciences has a consensus target price of $38.00, indicating a potential upside of 324.58%. Given Greenwich LifeSciences' higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in DNTH or GLSI? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor DNTH or GLSI? Dianthus Therapeutics received 18 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 96.30% of users gave Dianthus Therapeutics an outperform vote while only 44.44% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformDianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70%Greenwich LifeSciencesOutperform Votes844.44% Underperform Votes1055.56% Does the media favor DNTH or GLSI? In the previous week, Greenwich LifeSciences had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.17 beat Greenwich LifeSciences' score of 0.80 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDianthus Therapeutics beats Greenwich LifeSciences on 11 of the 18 factors compared between the two stocks. Remove Ads Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.65M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-11.196.8121.7017.82Price / SalesN/A225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book17.215.866.464.00Net Income-$8.89M$141.86M$3.20B$247.23M7 Day Performance-5.09%4.38%2.77%1.44%1 Month Performance-25.42%-12.76%-8.60%-6.26%1 Year Performance-37.93%-11.13%10.40%0.59% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.9679 of 5 stars$8.84-1.2%$38.00+329.9%-37.2%$116.20MN/A-11.053Earnings ReportUpcoming EarningsNews CoverageGap DownDNTHDianthus Therapeutics2.0416 of 5 stars$15.61-3.2%$54.33+248.1%-24.0%$501.47M$6.24M-6.2480News CoveragePositive NewsORGOOrganogenesis3.8748 of 5 stars$3.89+0.5%$5.50+41.4%+56.5%$493.36M$482.04M-64.83950Gap DownGHRSGH Research3.0805 of 5 stars$9.32-7.6%$30.86+231.1%-23.3%$484.90MN/A-11.8010Gap DownHigh Trading VolumeALMSAlumis2.4092 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/AGap DownHigh Trading VolumeQUREuniQure2.1694 of 5 stars$8.76-2.2%$38.80+342.9%+103.6%$473.72M$27.12M-1.77500Short Interest ↑Gap UpBCYCBicycle Therapeutics1.9283 of 5 stars$6.75-2.0%$29.14+331.7%-64.3%$467.11M$35.28M-2.05240Gap UpKURAKura Oncology4.0524 of 5 stars$5.76-2.2%$25.50+342.7%-68.3%$465.15M$53.88M-2.44130Gap DownURGNUroGen Pharma3.9023 of 5 stars$9.96-2.8%$38.20+283.5%-28.8%$459.10M$90.40M-3.16200Analyst ForecastNews CoveragePositive NewsMGTXMeiraGTx4.5264 of 5 stars$5.75+1.2%$24.50+326.1%-0.4%$453.42M$33.28M-4.75300Gap DownHigh Trading VolumeIMTXImmatics2.4826 of 5 stars$3.68+5.1%$16.67+352.9%-58.0%$439.23M$155.84M-5.58260Short Interest ↓News CoveragePositive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies DNTH Competitors ORGO Competitors GHRS Competitors ALMS Competitors QURE Competitors BCYC Competitors KURA Competitors URGN Competitors MGTX Competitors IMTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLSI Stock Free GLSI Stock Alerts